Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
|
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 50 条
  • [31] Relationship of the 21-gene recurrence score assay with tumor grade and KI67% in breast cancer.
    Bonta, Ioana
    Bonta, Dacian
    Loch, Michelle Marie
    Blanchard, Rita A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland
    McSorley, Lynda M.
    Tharmabala, Mehala
    Al Rahbi, Fathiya
    Keane, Fergus
    Evoy, Denis
    Geraghty, James G.
    Rothwell, Jane
    McCartan, Damian P.
    Greally, Megan
    O'Connor, Miriam
    O'Mahony, Deirdre
    Keane, Maccon
    Kennedy, Michael John
    O'Reilly, Seamus
    Millen, Steve J.
    Crown, John P.
    Kelly, Catherine M.
    Prichard, Ruth S.
    Quinn, Cecily M.
    Walshe, Janice M.
    CURRENT ONCOLOGY, 2024, 31 (03) : 1302 - 1310
  • [33] A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.
    Tsuchida, Yasue
    Ohde, Sachiko
    Nakamura, Ryota
    Kanada, Yoko
    Miura, Sakiko
    Takimoto, Masafumi
    Nakamura, Seigo
    Kanomata, Naoki
    Yamauchi, Hideko
    Hayashi, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
    Jegadeesh, Naresh K.
    Kim, Sunjin
    Prabhu, Roshan S.
    Oprea, Gabriela M.
    Yu, David S.
    Godette, Karen G.
    Zelnak, Amelia B.
    Mister, Donna
    Switchenko, Jeffrey M.
    Torres, Mylin A.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1088 - 1094
  • [35] The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
    Naresh K. Jegadeesh
    Sunjin Kim
    Roshan S. Prabhu
    Gabriela M. Oprea
    David S. Yu
    Karen G. Godette
    Amelia B. Zelnak
    Donna Mister
    Jeffrey M. Switchenko
    Mylin A. Torres
    Annals of Surgical Oncology, 2015, 22 : 1088 - 1094
  • [36] Survival outcome of adjuvant chemotherapy and high 21-gene recurrence score in early-stage breast cancer
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Farrugia, Mark
    Mikucki, Maryann
    Iovoli, Austin
    Shekher, Rohil
    Sood, Amit
    Singh, Anurag K.
    BREAST JOURNAL, 2021, 27 (01): : 27 - 34
  • [37] An analysis of the clinical and economic impact of the 21-gene recurrence score (RS) in invasive lobular early-stage breast cancer (ESBC) in Ireland
    Tharmabala, Mehala
    McSorley, Lynda
    Al Rahbi, Fathiya
    Denis, Evoy
    Geraghty, James G.
    Jane, Rothwell
    McCartan, Damian
    McDermott, Enda
    Keane, Maccon M.
    Kennedy, John
    O'Reilly, Seamus
    Millen, Steve
    Crown, John
    Smyth, Lilian Mary
    Kelly, Catherine Margaret
    Ruth, Prichard
    Quinn, Cecily
    Walshe, Janice M.
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
    Della Makower
    Juan Lin
    Xiaonan Xue
    Joseph A. Sparano
    npj Breast Cancer, 7
  • [39] Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
    Makower, Della
    Lin, Juan
    Xue, Xiaonan
    Sparano, Joseph A.
    NPJ BREAST CANCER, 2021, 7 (01)
  • [40] The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment
    Ethier, Josee-Lyne
    Amir, Eitan
    MOLECULAR DIAGNOSIS & THERAPY, 2016, 20 (04) : 307 - 313